RxDoctor Payments Data

Mercedes Jacobson, MD

Neurology · Philadelphia, PANPI 1770571754

Payments from drug & device makers

$178,270in general payments, 2019–2025

Across 91 payments — averaging $1959.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB SA$61K
  • UCB, Inc.$34K
  • Immedica Pharma US, Inc.$27K
  • Eli Lilly$26K
  • Sunovion Pharmaceuticals Inc.$23K
  • SK Life Science, Inc.$5K
  • plus $2K from 9 others

What the payments were for

  • Travel & lodging$92135%
  • Food & beverage$1,68463%
  • Education$532%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$178,270 in reported general payments places this provider in the 90th percentile of 941 neurology providers in Pennsylvania.

See all neurology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$38,640
Medicare patients
221
Services billed
423

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BriviactBrivaracetam262$494,568
EpidiolexCannabidiol (Cbd)33$200,852
FycompaPerampanel36$45,482
XcopriCenobamate39$45,048
NayzilamMidazolam38$35,443
Lacosamide233$31,508
Rufinamide18$26,214
ValtocoDiazepam26$17,597
Topiramate ErTopiramate11$12,818
Emgality PenGalcanezumab-Gnlm15$10,354
Clobazam92$9,111
Levetiracetam226$7,897
Carbamazepine ErCarbamazepine72$7,720
Lamotrigine160$6,429
Oxcarbazepine70$4,344

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Briviact, Nayzilam$34,203$530,010300 claims
SK Life Science, Inc.Xcopri$5,266$45,04839 claims
Neurelis, Inc.Valtoco$110$17,59726 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 941 neurology providers in Pennsylvania.

Other neurology in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →